The results showed that the quantity of CD14+CD16+ monocytes was higher in patients with multiple myeloma in contrast to the normal population, and this number was associated with increased bone destruction and bone resorption.[40] In addition, some studies have explored CD16+ as a potential marker of bone resorption precursor cells in patients with psoriatic arthritis (PSA). The gene discussed is CD14; the disease is plasma cell myeloma.